Canadian National PDA Treatment Study

计划入组 1,663 人 · 首次发布于 2020 年 4 月 15 日

Canadian Fabry Disease Initiative (CFDI) National Registry

计划入组 600 人 · 首次发布于 2007 年 4 月 3 日

The Canadian National Long QT Syndrome Registry

计划入组 1,051 人 · 首次发布于 2015 年 4 月 23 日

Autologous Human Schwann Cell Therapy(United States Department Of Defense)

ARM-X(Defence Therapeutics)

FP8v1-rTTHC

Department of National Defence and the Canadian Armed Forces

Canada

MINISTRY OF DEFENCE

India

National Bank of Canada

United Kingdom

Revive Therapeutics Advances Bucillamine Research for Nerve Agent Countermeasure in Collaboration with Canadian Defense Agency

DOD Grant Funds Research into Neuropsychiatric Symptoms of Parkinson's Disease

Revive Therapeutics Expands Bucillamine Patent Portfolio with North American Filings for Chemical Warfare Agent Treatment